Skip to main content

Table 1 Baseline characteristics of the study population.

From: Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

N 33
Sex (%)  
Male 51.5
Median Age (years) 11.7 (7.5–14.2)
Median % of Baseline CD4 counts 23.0 (19.5–32.0)
Median % of Baseline CD8 counts (%) 45.0 (33.5–57.5)
Median Baseline VL (HIV-RNA Log copies/ml) 4.0 (3.4–4.6)
Length of ARV therapy (months) 83.0 (49.0–119.0)
Length of PI exposure (months) 61.0 (38.0–73.0)
Length of NRTI exposure (months) 84.0 (49.0–119.0)
Length of NNRTI exposure (months) 5.0 (0.0–31.0)
Median number of previous PI exposure 2.0 (1–3.0)
Median number of NAMs 3.0 (1.5–4.0)
Median number of protease resistance mutations 5.0 (2.0–6.5)
  1. Results are expressed as median (IQR) (VL: viral load; ARV: antirretroviral treatment; PI: protease inhibitors; NAMs; nucleotide analogue mutations: M41L, D67N, K70R, L210W, T215Y/F y K219Q/E/R/S/N)